Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Retained Earnings: 2020-2024

Historic Retained Earnings for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Dec 2024 value amounting to -$360.2 million.

  • Tarsus Pharmaceuticals' Retained Earnings fell 24.08% to -$418.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$418.3 million, marking a year-over-year decrease of 24.08%. This contributed to the annual value of -$360.2 million for FY2024, which is 47.23% down from last year.
  • Latest data reveals that Tarsus Pharmaceuticals reported Retained Earnings of -$360.2 million as of FY2024, which was down 47.23% from -$244.7 million recorded in FY2023.
  • In the past 5 years, Tarsus Pharmaceuticals' Retained Earnings registered a high of -$32.8 million during FY2020, and its lowest value of -$360.2 million during FY2024.
  • For the 3-year period, Tarsus Pharmaceuticals' Retained Earnings averaged around -$237.9 million, with its median value being -$244.7 million (2023).
  • Data for Tarsus Pharmaceuticals' Retained Earnings shows a maximum YoY plummeted of 133.04% (in 2022) over the last 5 years.
  • Over the past 5 years, Tarsus Pharmaceuticals' Retained Earnings (Yearly) stood at -$32.8 million in 2020, then tumbled by 42.10% to -$46.7 million in 2021, then tumbled by 133.04% to -$108.8 million in 2022, then crashed by 124.94% to -$244.7 million in 2023, then plummeted by 47.23% to -$360.2 million in 2024.